Clinical Trial Update: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety of different doses of olaparib given with radium-223 in men with advanced prostate cancer with bone metastases;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Prostate Cancer Ajcc V8

Drugs mentioned

• Olaparib (Olaparib)
• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING